资讯

Crain's Chicago Business38 分钟

Cour Pharmaceuticals sets its sights on stopping Type 1 diabetes from progressing

The idea behind the tolerogenic nanoparticle treatment, CNP-103, is to reprogram the inflammatory autoimmune response that ...